Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Down 7.1%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)’s share price traded down 7.1% during mid-day trading on Wednesday . The stock traded as low as $11.63 and last traded at $11.68. 445,154 shares traded hands during trading, a decline of 44% from the average session volume of 791,847 shares. The stock had previously closed at $12.57.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ZNTL. HC Wainwright reiterated a “buy” rating and issued a $46.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Wednesday, February 28th. Wedbush lifted their price objective on shares of Zentalis Pharmaceuticals from $12.00 to $15.00 and gave the company a “neutral” rating in a research note on Wednesday, February 28th. Three analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $38.57.

Zentalis Pharmaceuticals Trading Up 0.7 %

The firm’s 50-day moving average is $14.08 and its 200-day moving average is $13.85. The firm has a market cap of $784.82 million, a price-to-earnings ratio of -2.44 and a beta of 1.73.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Tuesday, February 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.09. Analysts forecast that Zentalis Pharmaceuticals, Inc. will post -3.72 EPS for the current fiscal year.

Insiders Place Their Bets

In other Zentalis Pharmaceuticals news, CFO Melissa B. Epperly sold 2,573 shares of Zentalis Pharmaceuticals stock in a transaction on Monday, February 12th. The shares were sold at an average price of $11.44, for a total transaction of $29,435.12. Following the transaction, the chief financial officer now directly owns 451,449 shares of the company’s stock, valued at approximately $5,164,576.56. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 6.10% of the company’s stock.

Hedge Funds Weigh In On Zentalis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in ZNTL. China Universal Asset Management Co. Ltd. grew its position in Zentalis Pharmaceuticals by 132.2% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,809 shares of the company’s stock valued at $36,000 after buying an additional 1,030 shares during the period. Quest Partners LLC purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at about $38,000. Tower Research Capital LLC TRC lifted its holdings in Zentalis Pharmaceuticals by 252.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,615 shares of the company’s stock valued at $55,000 after purchasing an additional 2,589 shares during the last quarter. Exchange Traded Concepts LLC lifted its holdings in Zentalis Pharmaceuticals by 34.0% during the fourth quarter. Exchange Traded Concepts LLC now owns 5,989 shares of the company’s stock valued at $91,000 after purchasing an additional 1,519 shares during the last quarter. Finally, OneAscent Financial Services LLC purchased a new stake in Zentalis Pharmaceuticals during the fourth quarter valued at about $156,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.